Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2017-03-22 Capital/Financing Update
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 21, 2017, reporting the entry into a material definitive agreement related to an underwriting agreement for a public offering of American Depositary Shares (ADSs). It details the terms of the offering, the underwriting agreement, and related press releases. The content focuses on a financing transaction and capital raising activity. There are no financial statements or earnings data presented, nor is it an annual or quarterly report. The primary subject is the company's capital raising through an equity offering. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement or a brief notice.
2017-03-22 English
424B5
Capital/Financing Update Classification · 95% confidence The document is titled as a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) under a Registration Statement. It details the offering of American Depositary Shares (ADSs), including the number of shares, pricing, underwriting details, and risk factors. The content focuses on the terms of a securities offering, underwriting arrangements, and legal disclaimers. There is no financial performance data, earnings information, or management discussion of results. The document is a formal offering prospectus supplement related to a capital raising event. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), indicating it is the full prospectus supplement, not just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2017-03-22 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an offering of American Depositary Shares (ADSs). It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other legal and financial disclosures typical of a prospectus supplement. The document is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual offering document.
2017-03-21 English
3
Director's Dealing
2017-03-15 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 15, 2017, reporting the appointment of new executives and changes in the company's management team. It details the departure and appointment of directors and officers, including employment agreements and severance terms. There is no financial data or earnings information, nor is it a report or announcement of a report publication. The content clearly fits the category of announcements related to changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2017-03-15 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 14, 2017, by Adaptimmune Therapeutics plc. The key content is the release of an updated corporate presentation, referenced as Exhibit 99.1. The text explicitly states that the corporate presentation materials are attached and incorporated by reference. The document is relatively short (3512 characters) and primarily serves to announce the release of the presentation rather than containing the full presentation content itself. According to the 'Menu vs Meal' rule, such a document is an announcement of a report (the presentation) rather than the report itself. Therefore, the appropriate classification is 'Investor Presentation' (IP), as the document is about a corporate presentation for investors. Confidence is high given the clear description and standard SEC filing format.
2017-03-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.